Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected to reach over 100 billion dollars by 2030.

As exclusively revealed by the Daily Mail last week, the Wegovy Pill - the tablet form of the once-weekly Wegovy injection - has been greenlit by health officials.

A new prescription-only weight loss tablet has been approved for use in the UK for people who are overweight and have a related condition like high blood pressure

Regulator approval means patients who meet criteria such as having obesity will be able to purchase pills with private prescription

Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option backed by Phase 3 trial data.

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity…

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

Britain's regulator has approved Novo Nordisk's weight-loss pill, marking the UK's entry as the first European market for this oral obesity treatment.

Health chiefs have given the go-ahead for a tablet form of the weight loss drug to be used in the UK - full details of who can get it, how and when it will be available

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.